Vaccine Immunity and Inflammation in the Aging Person Living With HIV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-08

Study Completion Date

2029-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

NCT03039491

HIV Lipodystrophy Aging

COMPLETED EARLY_PHASE1

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751

Pneumococcal Infection

COMPLETED EARLY_PHASE1

Perturbing of HIV Reservoir With Immune Stimulation

NCT02707692

AIDS HIV

COMPLETED NA

Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.

NCT00148824

HIV Infections

COMPLETED PHASE2

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191

HIV Pneumonia Infections, Pneumococcal

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Persons living with HIV (PLWH) are at increased risk of chronic inflammation and the associated adverse health outcomes. There is considerable evidence that chronic inflammatory conditions like metabolic disease and autoimmune disorders as associated with weakened vaccine responses and existing vaccine studies in PLWH do not adequately sample older individuals who are disproportionately affected by this "inflammaging." We hypothesize the effect of age on poor vaccine responses is greater among PLWH given the additional burdens of HIV driven inflammation. The overall project goal is to examine this premise by measuring the impact of HIV status, age, and chronic immune activation on conjugate pneumococcal vaccine responses. We will study acute (30 day) and longer-term (2 year) immune responses following PCV vaccination, among a cohort of participants including 4 groups: a) older PLWH, age ≥50 (n=100), b) older HIV uninfected controls, age ≥50 (n=50), c) younger PLWH, age \<50 (n=50), d) younger HIV uninfected controls, age \<50 (n=50). With these cohorts, we will 1) Comprehensively characterize the impact of HIV and age on the immunogenicity of conjugate pneumococcal vaccination by longitudinally tracking adaptive vaccine-specific antibody, B cell and cluster of differentiation 4 T cell responses. We will compare these responses by age and HIV status. We will also 2) Determine the influence of chronic inflammation on vaccine-specific immunity among PLWH across the adult lifespan by measuring the associate between vaccine immunity and biomarkers of chronic inflammation. This project will provide valuable knowledge on how HIV and age influence vaccine immune responses with the hope of informing vaccine development and schedule to optimize the long-term health of persons living with HIV.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Age

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

1\) Some participants will receive this vaccine as part of routine clinical care, and we will coordinate our study visits based on the receipt of that vaccine. 2) Some participants will receive this vaccine outside of the Centers for Disease Control and Prevention recommended schedule, but as in accordance with FDA approved use and 3) Some participant who are receiving this vaccination outside of current FDA approval for a single dose in those above 18 by receiving a second dose.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pneumococcal Vaccination

All participants will receive a pneumococcal vaccine.

Group Type EXPERIMENTAL

Conjugate Pneumococcal Vaccine 20 (PCV20)

Intervention Type BIOLOGICAL

Vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conjugate Pneumococcal Vaccine 20 (PCV20)

Vaccine

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prevnar20

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\>=18 years
* HIV Diagnosis
* On Antiretroviral Therapy with HIV Viral Load\<200 within last year

* Age\>=18 years
* HIV Ag-Ab test negative

Exclusion Criteria

* Other significant immunosuppressing condition
* Age\< 18 years
* Pregnancy (at enrollment)
* Contraindication to pneumococcal vaccination
* Known contraindication to non-clinical blood draws (severe anemia last hemoglobin \<8g/dl)
* Subjects who, in the opinion of the Investigator, may be non-adherent to study schedules or procedures.
* Adults unable to consent
* Individuals with impaired ability to consent
* Incarceration at time of enrollment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes